Sandoz launches MabThera, Enbrel biosimilars in the UK
Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.
Read More
Tag: Erelzi
FDA green light for Sandoz’ Enbrel biosimilar
The US Food and Drug Administration has approved Sandoz’ biosimilar of Amgen’s blockbuster Enbrel.
Read More
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
